Athersys (NASDAQ:ATHX) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Athersys (NASDAQ:ATHX) in a report released on Sunday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Athersys Stock Performance

Athersys has a 12 month low of $0.01 and a 12 month high of $1.99. The firm has a market capitalization of $833,000.00, a price-to-earnings ratio of -0.01 and a beta of -0.90.

Athersys Company Profile

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.